Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 11.88 Million EUR | 1313.64% |
| 2022 | 841 Thousand EUR | 82.83% |
| 2021 | 460 Thousand EUR | -32.65% |
| 2020 | 683 Thousand EUR | -25.19% |
| 2019 | 913 Thousand EUR | 0.0% |
| 2018 | - EUR | -100.0% |
| 2017 | 6.53 Million EUR | 0.0% |
| 2016 | - EUR | -100.0% |
| 2015 | 1.07 Million EUR | -44.44% |
| 2014 | 1.92 Million EUR | -0.31% |
| 2013 | 1.93 Million EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 9000.00 EUR | -75.68% |
| 2009 | 37 Thousand EUR | -43.94% |
| 2008 | 66 Thousand EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | -100.0% |
| 2005 | 4000.00 EUR | -90.24% |
| 2004 | 41 Thousand EUR | 173.33% |
| 2003 | 15 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 356 Thousand EUR | -18.91% |
| 2023 Q1 | 439 Thousand EUR | -47.8% |
| 2023 Q3 | 11.88 Million EUR | 3239.53% |
| 2023 FY | 11.88 Million EUR | 1313.64% |
| 2023 Q4 | 11.88 Million EUR | 0.0% |
| 2022 Q2 | 1 Million EUR | -1.37% |
| 2022 Q3 | 966 Thousand EUR | -3.98% |
| 2022 Q4 | 841 Thousand EUR | -12.94% |
| 2022 FY | 841 Thousand EUR | 82.83% |
| 2022 Q1 | 1.02 Million EUR | 121.74% |
| 2021 FY | 460 Thousand EUR | -32.65% |
| 2021 Q4 | 460 Thousand EUR | -11.54% |
| 2021 Q2 | 577 Thousand EUR | -8.99% |
| 2021 Q3 | 520 Thousand EUR | -9.88% |
| 2021 Q1 | 634 Thousand EUR | -7.17% |
| 2020 Q2 | 807 Thousand EUR | -6.92% |
| 2020 Q1 | 867 Thousand EUR | -5.04% |
| 2020 Q4 | 683 Thousand EUR | -8.2% |
| 2020 FY | 683 Thousand EUR | -25.19% |
| 2020 Q3 | 744 Thousand EUR | -7.81% |
| 2019 Q3 | 973 Thousand EUR | -3.57% |
| 2019 FY | 913 Thousand EUR | 0.0% |
| 2019 Q2 | 1 Million EUR | 51.05% |
| 2019 Q1 | 668 Thousand EUR | 0.0% |
| 2019 Q4 | 913 Thousand EUR | -6.17% |
| 2018 FY | - EUR | -100.0% |
| 2018 Q4 | - EUR | -100.0% |
| 2018 Q2 | 6.81 Million EUR | 2.11% |
| 2018 Q1 | 6.67 Million EUR | 2.11% |
| 2018 Q3 | 6.95 Million EUR | 2.08% |
| 2017 FY | 6.53 Million EUR | 0.0% |
| 2017 Q4 | 6.53 Million EUR | 1.93% |
| 2017 Q3 | 6.41 Million EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2016 Q2 | 535 Thousand EUR | -16.67% |
| 2016 Q4 | - EUR | -100.0% |
| 2016 FY | - EUR | -100.0% |
| 2016 Q1 | 642 Thousand EUR | -40.0% |
| 2016 Q3 | 535 Thousand EUR | 0.0% |
| 2015 Q1 | 1.71 Million EUR | -11.11% |
| 2015 FY | 1.07 Million EUR | -44.44% |
| 2015 Q2 | 1.39 Million EUR | -18.75% |
| 2015 Q4 | 1.07 Million EUR | -9.09% |
| 2015 Q3 | 1.17 Million EUR | -15.38% |
| 2014 Q4 | 1.92 Million EUR | -14.29% |
| 2014 Q2 | 2.17 Million EUR | 10.51% |
| 2014 FY | 1.92 Million EUR | -0.31% |
| 2014 Q1 | 1.96 Million EUR | 1.92% |
| 2014 Q3 | 2.24 Million EUR | 3.26% |
| 2013 Q3 | 263 Thousand EUR | 0.0% |
| 2013 Q4 | 1.93 Million EUR | 634.6% |
| 2013 FY | 1.93 Million EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2011 Q1 | 2000.00 EUR | -77.78% |
| 2011 Q2 | - EUR | -100.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 FY | - EUR | -100.0% |
| 2010 Q4 | 9000.00 EUR | -43.75% |
| 2010 FY | 9000.00 EUR | -75.68% |
| 2010 Q1 | 30 Thousand EUR | -18.92% |
| 2010 Q2 | - EUR | -100.0% |
| 2010 Q3 | 16 Thousand EUR | 0.0% |
| 2009 Q4 | 37 Thousand EUR | 0.0% |
| 2009 FY | 37 Thousand EUR | -43.94% |
| 2008 FY | 66 Thousand EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | 4000.00 EUR | -90.24% |
| 2004 FY | 41 Thousand EUR | 173.33% |
| 2003 FY | 15 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | -430.746% |
| Arrayit Corporation | 1.07 Million USD | -1002.679% |
| Atlantic International Corp. | 2.93 Million USD | -305.691% |
| Biocept, Inc. | 12.1 Million USD | 1.819% |
| Bioqual, Inc. | 3.58 Million USD | -231.44% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -16272.486% |
| DermTech, Inc. | 54.39 Million USD | 78.143% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 471.86 Million USD | 97.481% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | -145.942% |
| iMD Companies, Inc. | 1.12 Million USD | -961.351% |
| IDenta Corp. | 789.14 Thousand USD | -1406.529% |
| Interpace Biosciences, Inc. | 11.19 Million USD | -6.225% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -27015.331% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | -47.779% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | -210.744% |
| NovelStem International Corp. | 3.57 Million USD | -232.589% |
| Optigenex Inc. | 8.94 Million USD | -32.972% |
| PharmChem, Inc. | 77.35 Thousand USD | -15269.432% |
| Proteome Sciences plc | 17.15 Million USD | 30.693% |
| Response Genetics, Inc | 6.37 Million USD | -86.548% |
| Rennova Health, Inc. | 15.32 Million USD | 22.445% |
| RushNet, Inc. | 4.82 Million USD | -146.495% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -5642.398% |
| Stella Diagnostics Inc. | 6.2 Million USD | -91.732% |
| StageZero Life Sciences Ltd. | 1.8 Million USD | -560.454% |
| Todos Medical Ltd. | 38.34 Million USD | 68.998% |